Cohn LA, DeClue AE, Cohen RL, Reinero CR. Effects of fluticasone propionate dosage in an experimental model of feline asthma. J Feline Med Surg. 2010;12(2):91-96.
Feline inflammatory bronchial diseases (e.g., asthma and chronic bronchitis) are common lower respiratory diseases in cats. The mainstay of therapy for inflammatory airway disease is the administration of glucocorticoids (GCs). Glucocorticoid use is indicated for the treatment of asthma and chronic bronchitis, yet GCs are associated with the potential for adverse side effects. Systemic side effects and the resultant adverse effects can be minimized with the use of topical application of GC to the airways via an inhalational delivery system. The authors utilized a randomized, cross-over study design to investigate the ability of three different dosages of the inhalant GC fluticasone proprionate (Flovent HFA) delivered by a metered dose inhaler to ameliorate eosinophilic airway inflammation in cats with experimentally induced allergic airway inflammation. In addition, suppression of the hypothalamic-pituitary-adrenal axis at each dose was assessed. Fluticasone was administered at dosages of 44,110, or 220 mcg administered every 12 hours to six cats. All three-dosage regimens of fluticasone resulted in significant amelioration of airway eosinophilia. None of the dose regimens tested caused HPAA suppression. The conclusion was that a twice-daily dose of 44 mcg fluticasone should be evaluated for the management of naturally occurring inflammatory bronchial disease in cats. This is important because fluticasone is a costly drug, and the lower strengths are less expensive than the higher strengths. [VT]
Padrid P. Use of inhaled medications to treat respiratory diseases in dogs and cats. J Am Anim Hosp Assoc. 2006;42(2):165-169.
Reinero CR, Delgado C, Spinka C, DeClue AE, Dhand R. Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats. Int Arch Allergy Immunol. 2009;150(1):43-50.